Click the blue text Follow us This Issue Highlights In recent years, the field of tumor immunotherapy has welcomed an important new target—DLL3. As a ligand of the Notch signaling pathway, DLL3 (Delta-like ligand 3) plays a key role in the progression of various malignant tumors, particularly in small cell lung cancer (SCLC) and neuroendocrine … Read more
Bispecific antibodies are antibodies that can bind to two different antigens simultaneously, providing greater flexibility in their mechanisms of action. Bispecific antibodies have achieved success in hematologic malignancies, with two bispecific antibodies already approved for market: blinatumomab, targeting CD19/CD3, and Mosunetuzumab, targeting CD20/CD3. Additionally, numerous bispecific antibodies targeting hematologic cancers have shown impressive efficacy in … Read more
▎Armstrong The 2025 American Association for Cancer Research (AACR) Annual Meeting will be held from April 25-30 in Chicago, USA. Recently, the conference abstracts have been released, showcasing a significant presence of Chinese innovations. In the field of ADCs, the majority of reports come from Chinese pharmaceutical companies, with nearly 100 innovative ADCs covering various … Read more
Antibody-drug conjugates (ADC) have become one of the most sought-after methods for treating cancer patients. Recently, several notable deals have taken place between small biotech companies developing ADCs and large companies looking to enhance their oncology pipelines. The recent Kangfang AK112 incident has brought bispecific antibodies into the spotlight, with some discussing the viability of … Read more